lifestyle.marketresearchjournals.com

Author: Diakonos Oncology

Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026

May 3, 2026
/C O R R E C T I O N — Diakonos Oncology/

April 1, 2026
Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026

March 18, 2026
Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study

February 18, 2026
Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase

December 19, 2025
Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma

December 16, 2025